-
公开(公告)号：US5182368A
公开(公告)日：1993-01-26
申请号：US708075
申请日：1991-05-24
Applicant: Jeffrey A. Ledbetter , Edward A. Clark
Inventor： Jeffrey A. Ledbetter , Edward A. Clark
IPC: A61K38/00 , A61K47/48 , C07K14/54 , C07K14/715 , C07K16/28
CPC classification number: C07K14/715 , A61K47/48561 , C07K14/54 , C07K16/28 , A61K38/00 , C07K2317/74 , Y10S530/866
Abstract: A new B-cell receptor, Bp50, a 50 kilodalton polypeptide, that functions in B-cell proliferation is described. Ligands such as lymphokines, antibody molecules or the Fv fragments of antibody molecules that bind to Bp50 and augment the proliferation of activated B-cells can be used to regulate B-cell proliferation or differentiation.
-
公开(公告)号：US10307481B2
公开(公告)日：2019-06-04
申请号：US11493132
申请日：2006-07-25
Applicant: Laura S. Grosmaire , Martha S. Hayden-Ledbetter , Jeffrey A. Ledbetter , Peter A. Thompson , Sandy A. Simon , William Brady
Inventor： Laura S. Grosmaire , Martha S. Hayden-Ledbetter , Jeffrey A. Ledbetter , Peter A. Thompson , Sandy A. Simon , William Brady
Abstract: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.
-
公开(公告)号：US08841416B2
公开(公告)日：2014-09-23
申请号：US13197731
申请日：2011-08-03
Applicant: Jeffrey A. Ledbetter , Martha Hayden-Ledbetter , Keith Elkon , Xizhang Sun
Inventor： Jeffrey A. Ledbetter , Martha Hayden-Ledbetter , Keith Elkon , Xizhang Sun
IPC: C07K17/00 , C07K16/00 , A61K39/02 , A61K39/002 , A61K39/385 , C12N9/96 , C12N9/22 , C12N11/06 , C12P21/08 , A61K38/00
CPC classification number: C12N9/22 , A61K38/00 , C07K16/18 , C07K2319/30 , C12N9/96 , C12N11/06 , C12Y301/27005 , Y02P20/582
Abstract: Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.
Abstract translation: 杂交核酸酶分子和用于治疗哺乳动物免疫相关疾病或病症的方法和用于治疗哺乳动物免疫相关疾病的药物组合物。
-
公开(公告)号：US20140127203A1
公开(公告)日：2014-05-08
申请号：US13815722
申请日：2013-03-15
Applicant: PETER ARMSTRONG THOMPSON , JEFFREY A. LEDBETTER , MARTHA SUSAN HAYDEN-LEDBETTER , LAURA SUE GROSMAIRE , ROBERT BADER , WILLIAM BRADY
Inventor： PETER ARMSTRONG THOMPSON , JEFFREY A. LEDBETTER , MARTHA SUSAN HAYDEN-LEDBETTER , LAURA SUE GROSMAIRE , ROBERT BADER , WILLIAM BRADY
IPC: C07K16/18
CPC classification number: C07K16/28 , A61K2039/505 , A61K2039/507 , C07K16/18 , C07K16/2803 , C07K16/2809 , C07K16/2818 , C07K16/2827 , C07K16/2833 , C07K16/2851 , C07K16/2875 , C07K16/2878 , C07K16/2887 , C07K16/2896 , C07K16/30 , C07K16/46 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/52 , C07K2317/53 , C07K2317/622 , C07K2317/64 , C07K2317/732 , C07K2317/734 , C07K2319/30
Abstract: Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.
Abstract translation: 提供具有免疫球蛋白效应子功能的多价结合肽，包括双特异性结合肽，以及编码核酸，载体和宿主细胞以及制备这些肽的方法和使用这些肽治疗或预防各种疾病的方法 ，疾病或病症，以及改善与这种疾病，病症或病症相关的至少一种症状。
-
公开(公告)号：US20120225066A1
公开(公告)日：2012-09-06
申请号：US13197731
申请日：2011-08-03
Applicant: Jeffrey A. Ledbetter , Martha Hayden-Ledbetter , Keith Elkon , Xizhang Sun
Inventor： Jeffrey A. Ledbetter , Martha Hayden-Ledbetter , Keith Elkon , Xizhang Sun
IPC: A61K39/395 , C12N15/63 , C12N1/21 , C12N1/19 , A61P1/04 , C12N5/10 , C12N15/62 , A61P19/02 , A61P37/00 , A61P15/08 , C12N9/96 , C12N1/15
CPC classification number: C12N9/22 , A61K38/00 , C07K16/18 , C07K2319/30 , C12N9/96 , C12N11/06 , C12Y301/27005 , Y02P20/582
Abstract: Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.
Abstract translation: 杂交核酸酶分子和用于治疗哺乳动物免疫相关疾病或病症的方法和用于治疗哺乳动物免疫相关疾病的药物组合物。
-
Patent Agency Ranking
公开(公告)号：US08106161B2
公开(公告)日：2012-01-31
申请号：US11088693
申请日：2005-03-23
Applicant: Jeffrey A. Ledbetter , Martha S. Hayden-Ledbetter
Inventor： Jeffrey A. Ledbetter , Martha S. Hayden-Ledbetter
IPC: C07K16/00
CPC classification number: C07K16/46 , A61K2039/505 , C07K16/2809 , C07K16/2818 , C07K16/2878 , C07K16/2896 , C07K16/462 , C07K2317/22 , C07K2317/24 , C07K2317/53 , C07K2317/622 , C07K2317/64 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/30
Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.
-
公开(公告)号：US20110033483A1
公开(公告)日：2011-02-10
申请号：US12304562
申请日：2007-06-12
Applicant: Peter Armstrong Thompson , Jeffrey A. Ledbetter , Martha Susan Hayden-Ledbetter , Laura Sue Grosmaire , Robert Bader , William Brady
Inventor： Peter Armstrong Thompson , Jeffrey A. Ledbetter , Martha Susan Hayden-Ledbetter , Laura Sue Grosmaire , Robert Bader , William Brady
IPC: A61K39/395 , C07K19/00 , C07K16/46 , C07H21/00 , C12N15/63 , C12N5/10 , A61P35/00 , A61P29/00 , A61P3/10 , A61P19/02 , A61P11/06 , A61P25/00 , A61P17/06 , A61P37/06
CPC classification number: C07K16/28 , A61K2039/505 , A61K2039/507 , C07K16/18 , C07K16/2803 , C07K16/2809 , C07K16/2818 , C07K16/2827 , C07K16/2833 , C07K16/2851 , C07K16/2875 , C07K16/2878 , C07K16/2887 , C07K16/2896 , C07K16/30 , C07K16/46 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/52 , C07K2317/53 , C07K2317/622 , C07K2317/64 , C07K2317/732 , C07K2317/734 , C07K2319/30
Abstract: Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.
Abstract translation: 提供具有免疫球蛋白效应子功能的多价结合肽，包括双特异性结合肽，以及编码核酸，载体和宿主细胞以及制备这些肽的方法和使用这些肽治疗或预防各种疾病的方法 ，疾病或病症，以及改善与这种疾病，病症或病症相关的至少一种症状。
-
48.发明申请B-CELL REDUCTION USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES 审中-公开使用CD37特异性和CD20特异性结合分子的B细胞减少公开(公告)号：US20090214539A1
公开(公告)日：2009-08-27
申请号：US12437507
申请日：2009-05-07
Applicant: Laura S. Grosmaire , Martha S. Hayden-Ledbetter , Jeffrey A. Ledbetter , Peter A. Thompson , Sandy A. Simon , William Brady
Inventor： Laura S. Grosmaire , Martha S. Hayden-Ledbetter , Jeffrey A. Ledbetter , Peter A. Thompson , Sandy A. Simon , William Brady
IPC: A61K39/395 , C07K16/18
Abstract: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.
Abstract translation: 本发明通常提供使用CD37特异性结合分子的个体中B细胞减少的方法。 特别地，本发明提供了使用单独的CD37-特异性结合分子或CD37-特异性结合分子和CD20-特异性结合分子的组合（在某些情况下是协同组合）的B细胞减少的方法。 本发明还提供了用于治疗涉及异常B细胞活性的疾病的材料和方法。 此外，本发明提供了人源化的CD37特异性结合分子。
-
49.发明申请B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules 审中-公开使用CD37特异性和CD20特异性结合分子的B细胞减少公开(公告)号：US20080279850A1
公开(公告)日：2008-11-13
申请号：US12101701
申请日：2008-04-11
Applicant: William Brady , Martha S. Hayden-Ledbetter , Jeffrey A. Ledbetter , Sandy A. Simon , Peter A. Thompson
Inventor： William Brady , Martha S. Hayden-Ledbetter , Jeffrey A. Ledbetter , Sandy A. Simon , Peter A. Thompson
CPC classification number: C07K16/2887 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/2896 , C07K2317/24 , C07K2317/53 , C07K2317/56 , C07K2317/622 , C07K2317/72 , C07K2317/73 , C07K2317/732 , C07K2317/734 , A61K2300/00
Abstract: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.
Abstract translation: 本发明通常提供使用CD37特异性结合分子的个体中B细胞减少的方法。 特别地，本发明提供了使用单独的CD37-特异性结合分子或CD37-特异性结合分子和CD20-特异性结合分子的组合（在某些情况下是协同组合）的B细胞减少的方法。 本发明还提供了用于治疗涉及异常B细胞活性的疾病的材料和方法。 此外，本发明提供了人源化的CD37特异性结合分子。
-
公开(公告)号：US06887471B1
公开(公告)日：2005-05-03
申请号：US09454651
申请日：1999-12-06
Applicant: Peter S. Linsley , Jeffrey A. Ledbetter , Nitin K. Damle , William Brady
Inventor： Peter S. Linsley , Jeffrey A. Ledbetter , Nitin K. Damle , William Brady
IPC: A61K38/00 , C07K14/705 , C07K14/715 , C07K16/00 , C07K16/28 , A61K38/17 , C12N15/12 , C12N15/63
CPC classification number: C07K16/247 , A61K38/00 , A61K2039/505 , C07K14/70521 , C07K14/7155 , C07K16/00 , C07K16/2818 , C07K16/2827 , C07K2317/34 , C07K2317/73 , C07K2319/00 , C07K2319/30 , Y10S514/885
Abstract: This invention provides methods for regulating T cell interactions with B7 positive cells. Methods are provided for using B7 antigen, its fragments and derivatives reactive with CTLA4 receptor, to regulate CTLA4 positive T cell responses, and immune responses mediated by T cells.
Abstract translation: 本发明提供了调节与B7阳性细胞的T细胞相互作用的方法。 提供了使用B7抗原及其与CTLA4受体反应的衍生物调节CTLA4阳性T细胞应答和T细胞介导的免疫应答的方法。
-
-
-
-
-
-
-
-
-
Search Results
95
records
(took 0.06 seconds)
